OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado. Show more

6707 Winchester Circle, Boulder, CO, 80301, United States

Biotechnology

Healthcare

Market Cap

51.21M

52 Wk Range

$1.70 - $5.28

Previous Close

$3.78

Open

$3.86

Volume

343,635

Day Range

$3.80 - $4.15

Enterprise Value

-18.43M

Cash

70.33M

Avg Qtr Burn

-13.04M

Insider Ownership

1.69%

Institutional Own.

83.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OKI-219 +/- Fulvestrant or Trastuzumab Details Breast cancer, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavodelpar (REN001) Details long-chain fatty acid oxidation disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mavodelpar (REN001) Details primary mitochondrial myopathies	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.